Expression pattern of PD-1/PD-L1 in primary liver cancer with clinical correlation

Liver Int. 2023 Sep;43(9):1995-2001. doi: 10.1111/liv.15666. Epub 2023 Jul 9.

Abstract

Immunotherapy, including ICIs, has emerged as an invaluable treatment option for advanced PLC. Nevertheless, the expression patterns of PD-L1 and PD-1 in PLC remain incompletely understood. In this study, the expression pattern and clinical correlation of PD-L1 and PD-1 were analysed in 5245 PLC patients. The positivity rates of PD-L1 and PD-1 were very low in the patient PLCs, but the positivity rates of PD-L1 and PD-1 were higher in the ICC and cHCC-ICC than in HCC. The expression of PD-L1 and PD-1 correlated with the malignant phenotypes and clinicopathological characteristics of PLC. Interestingly, PD-1 positivity might serve as an independent prognostic factor. Based on a systematic analysis of a large amount of PLC tissues, we proposed a novel classification of PD-1/PD-L1 expression in HCC and ICC. In light of this stratification, we observed a close correlation between PD-L1 levels and PD-1 expression in HCC and ICC.

Keywords: immune checkpoint; immunotherapy; primary liver cancer; programmed cell death 1 ligand 1; programmed cell death protein 1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B7-H1 Antigen
  • Carcinoma, Hepatocellular* / pathology
  • Humans
  • Immunotherapy
  • Liver Neoplasms* / pathology
  • Programmed Cell Death 1 Receptor

Substances

  • Programmed Cell Death 1 Receptor
  • B7-H1 Antigen